Responses to Corticotrophin-Releasing Hormone and Dexamethasone in a Large Series of Human Adrenocorticotrophic Hormone-Secreting Pituitary Adenomas In Vitro Reveal Manifold Corticotroph Tumoural Phenotypes

F. Pecori Giraldi, L. Pagliardini, M. F. Cassarino, M. Losa, G. Lasio, F. Cavagnini

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Patients with Cushing's disease are known to present a variable secretory response to stimulatory and inhibitory challenges. Evaluation of the secretory behaviour of pituitary adrenocorticotrophic hormone (ACTH)-secreting adenomas in vitro aids in the comprehension of its behaviour in vivo; however, given the small size of these tumours and the consequent paucity of material available to in vitro studies, a comprehensive study on the secretory behaviour of human corticotroph tumours has not yet been performed. The present study aimed to assess the spectrum of responses to the two main corticotroph modulators, corticotrophin-releasing hormone (CRH) and dexamethasone, in a large series of human ACTH-secreting pituitary tumours. Seventy-two ACTH-secreting pituitary tumours were collected during surgery and established in culture. Specimens were incubated with 10nm CRH and/or 10nm dexamethasone for 4h and 24h. Secretion in unstimulated, control wells was set at 100% and changes in ACTH concentrations by at least 20% were considered as responses. Parallel experiments in 12 rat anterior pituitary primary cultures were evaluated. A marked ACTH increase was observed during incubation with CRH in 70% of tumoural specimens at 4h (range 124-3500% of control wells) and in 57% at 24h (range 122-3323%). Dexamethasone reduced ACTH secretion in almost 50% of tumours (range 78-2% of control at 4h; 76-3% at 24h), whereas it did not affect ACTH medium levels in 30% of specimens and induced a paradoxical ACTH increase in 20% of tumours (range 130-327% of control at 4h; 156-348% at 24h). By comparison, CRH uniformly increased ACTH levels in rat anterior pituitary primary cultures (mean 745±84% at 4h; 347±25% at 24h), whereas dexamethasone decreased ACTH levels by 40-50% in all experiments. In conclusion, the present study of a large series of human ACTH-secreting pituitary tumours in vitro revealed a considerable variability in the responses to CRH and dexamethasone. This finding indicates the existence of multiple corticotroph tumoural phenotypes and may account for the different responses to physiological and pharmacological modulators in vivo.

Original languageEnglish
Pages (from-to)1214-1221
Number of pages8
JournalJournal of Neuroendocrinology
Volume23
Issue number12
DOIs
Publication statusPublished - Dec 2011

Fingerprint

Corticotrophs
Corticotropin-Releasing Hormone
Pituitary Neoplasms
Adrenocorticotropic Hormone
Dexamethasone
Phenotype
Neoplasms
In Vitro Techniques
Pituitary ACTH Hypersecretion
Pituitary Hormones
Adenoma

Keywords

  • ACTH
  • Corticotrophin-releasing hormone
  • Cushing's disease
  • Glucocorticoid negative feedback

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism
  • Endocrine and Autonomic Systems
  • Cellular and Molecular Neuroscience

Cite this

@article{27c5e8498bcf483dae7185768319502c,
title = "Responses to Corticotrophin-Releasing Hormone and Dexamethasone in a Large Series of Human Adrenocorticotrophic Hormone-Secreting Pituitary Adenomas In Vitro Reveal Manifold Corticotroph Tumoural Phenotypes",
abstract = "Patients with Cushing's disease are known to present a variable secretory response to stimulatory and inhibitory challenges. Evaluation of the secretory behaviour of pituitary adrenocorticotrophic hormone (ACTH)-secreting adenomas in vitro aids in the comprehension of its behaviour in vivo; however, given the small size of these tumours and the consequent paucity of material available to in vitro studies, a comprehensive study on the secretory behaviour of human corticotroph tumours has not yet been performed. The present study aimed to assess the spectrum of responses to the two main corticotroph modulators, corticotrophin-releasing hormone (CRH) and dexamethasone, in a large series of human ACTH-secreting pituitary tumours. Seventy-two ACTH-secreting pituitary tumours were collected during surgery and established in culture. Specimens were incubated with 10nm CRH and/or 10nm dexamethasone for 4h and 24h. Secretion in unstimulated, control wells was set at 100{\%} and changes in ACTH concentrations by at least 20{\%} were considered as responses. Parallel experiments in 12 rat anterior pituitary primary cultures were evaluated. A marked ACTH increase was observed during incubation with CRH in 70{\%} of tumoural specimens at 4h (range 124-3500{\%} of control wells) and in 57{\%} at 24h (range 122-3323{\%}). Dexamethasone reduced ACTH secretion in almost 50{\%} of tumours (range 78-2{\%} of control at 4h; 76-3{\%} at 24h), whereas it did not affect ACTH medium levels in 30{\%} of specimens and induced a paradoxical ACTH increase in 20{\%} of tumours (range 130-327{\%} of control at 4h; 156-348{\%} at 24h). By comparison, CRH uniformly increased ACTH levels in rat anterior pituitary primary cultures (mean 745±84{\%} at 4h; 347±25{\%} at 24h), whereas dexamethasone decreased ACTH levels by 40-50{\%} in all experiments. In conclusion, the present study of a large series of human ACTH-secreting pituitary tumours in vitro revealed a considerable variability in the responses to CRH and dexamethasone. This finding indicates the existence of multiple corticotroph tumoural phenotypes and may account for the different responses to physiological and pharmacological modulators in vivo.",
keywords = "ACTH, Corticotrophin-releasing hormone, Cushing's disease, Glucocorticoid negative feedback",
author = "{Pecori Giraldi}, F. and L. Pagliardini and Cassarino, {M. F.} and M. Losa and G. Lasio and F. Cavagnini",
year = "2011",
month = "12",
doi = "10.1111/j.1365-2826.2011.02213.x",
language = "English",
volume = "23",
pages = "1214--1221",
journal = "Journal of Neuroendocrinology",
issn = "0953-8194",
publisher = "Wiley-Blackwell",
number = "12",

}

TY - JOUR

T1 - Responses to Corticotrophin-Releasing Hormone and Dexamethasone in a Large Series of Human Adrenocorticotrophic Hormone-Secreting Pituitary Adenomas In Vitro Reveal Manifold Corticotroph Tumoural Phenotypes

AU - Pecori Giraldi, F.

AU - Pagliardini, L.

AU - Cassarino, M. F.

AU - Losa, M.

AU - Lasio, G.

AU - Cavagnini, F.

PY - 2011/12

Y1 - 2011/12

N2 - Patients with Cushing's disease are known to present a variable secretory response to stimulatory and inhibitory challenges. Evaluation of the secretory behaviour of pituitary adrenocorticotrophic hormone (ACTH)-secreting adenomas in vitro aids in the comprehension of its behaviour in vivo; however, given the small size of these tumours and the consequent paucity of material available to in vitro studies, a comprehensive study on the secretory behaviour of human corticotroph tumours has not yet been performed. The present study aimed to assess the spectrum of responses to the two main corticotroph modulators, corticotrophin-releasing hormone (CRH) and dexamethasone, in a large series of human ACTH-secreting pituitary tumours. Seventy-two ACTH-secreting pituitary tumours were collected during surgery and established in culture. Specimens were incubated with 10nm CRH and/or 10nm dexamethasone for 4h and 24h. Secretion in unstimulated, control wells was set at 100% and changes in ACTH concentrations by at least 20% were considered as responses. Parallel experiments in 12 rat anterior pituitary primary cultures were evaluated. A marked ACTH increase was observed during incubation with CRH in 70% of tumoural specimens at 4h (range 124-3500% of control wells) and in 57% at 24h (range 122-3323%). Dexamethasone reduced ACTH secretion in almost 50% of tumours (range 78-2% of control at 4h; 76-3% at 24h), whereas it did not affect ACTH medium levels in 30% of specimens and induced a paradoxical ACTH increase in 20% of tumours (range 130-327% of control at 4h; 156-348% at 24h). By comparison, CRH uniformly increased ACTH levels in rat anterior pituitary primary cultures (mean 745±84% at 4h; 347±25% at 24h), whereas dexamethasone decreased ACTH levels by 40-50% in all experiments. In conclusion, the present study of a large series of human ACTH-secreting pituitary tumours in vitro revealed a considerable variability in the responses to CRH and dexamethasone. This finding indicates the existence of multiple corticotroph tumoural phenotypes and may account for the different responses to physiological and pharmacological modulators in vivo.

AB - Patients with Cushing's disease are known to present a variable secretory response to stimulatory and inhibitory challenges. Evaluation of the secretory behaviour of pituitary adrenocorticotrophic hormone (ACTH)-secreting adenomas in vitro aids in the comprehension of its behaviour in vivo; however, given the small size of these tumours and the consequent paucity of material available to in vitro studies, a comprehensive study on the secretory behaviour of human corticotroph tumours has not yet been performed. The present study aimed to assess the spectrum of responses to the two main corticotroph modulators, corticotrophin-releasing hormone (CRH) and dexamethasone, in a large series of human ACTH-secreting pituitary tumours. Seventy-two ACTH-secreting pituitary tumours were collected during surgery and established in culture. Specimens were incubated with 10nm CRH and/or 10nm dexamethasone for 4h and 24h. Secretion in unstimulated, control wells was set at 100% and changes in ACTH concentrations by at least 20% were considered as responses. Parallel experiments in 12 rat anterior pituitary primary cultures were evaluated. A marked ACTH increase was observed during incubation with CRH in 70% of tumoural specimens at 4h (range 124-3500% of control wells) and in 57% at 24h (range 122-3323%). Dexamethasone reduced ACTH secretion in almost 50% of tumours (range 78-2% of control at 4h; 76-3% at 24h), whereas it did not affect ACTH medium levels in 30% of specimens and induced a paradoxical ACTH increase in 20% of tumours (range 130-327% of control at 4h; 156-348% at 24h). By comparison, CRH uniformly increased ACTH levels in rat anterior pituitary primary cultures (mean 745±84% at 4h; 347±25% at 24h), whereas dexamethasone decreased ACTH levels by 40-50% in all experiments. In conclusion, the present study of a large series of human ACTH-secreting pituitary tumours in vitro revealed a considerable variability in the responses to CRH and dexamethasone. This finding indicates the existence of multiple corticotroph tumoural phenotypes and may account for the different responses to physiological and pharmacological modulators in vivo.

KW - ACTH

KW - Corticotrophin-releasing hormone

KW - Cushing's disease

KW - Glucocorticoid negative feedback

UR - http://www.scopus.com/inward/record.url?scp=81855194747&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=81855194747&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2826.2011.02213.x

DO - 10.1111/j.1365-2826.2011.02213.x

M3 - Article

C2 - 21883533

AN - SCOPUS:81855194747

VL - 23

SP - 1214

EP - 1221

JO - Journal of Neuroendocrinology

JF - Journal of Neuroendocrinology

SN - 0953-8194

IS - 12

ER -